The importance and benefits of hepatitis A prevention in chronic liver disease patients

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue SUPPL., 2004, Pages

  Cooksley, Graham ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VACCINE;

ARTICLE; CHINA; CHRONIC LIVER DISEASE; COST EFFECTIVENESS ANALYSIS; EPIDEMIC; FATALITY; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNIZATION; INCIDENCE; ISRAEL; LIVER NECROSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; SPAIN; TAIWAN; UNITED STATES; VACCINATION; VIRUS INFECTION;

EID: 1542407374     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2003.03394.x     Document Type: Article

References (14)

1. Fukotmoto Y, Okita K, Konishi T et al. Hepatitis A infection in chronic carriers of hepatitis B virus. In: Sung J-L, Chen D-S, eds. Viral Hepatitis and Hepatocellular Carcinoma. Amsterdam: Excerpta Medica, 1990; 43-8.
2. Zachoval R, Roggendorf M, Deinhardt F. Hepatitis A infection in chronic carriers of hepatitis B virus. Hepatology 1983; 3: 528-91.
3. Yao G. Clinical spectrum and natural history of viral hepatitis A in 1998 Shanghai epidemic. In: Hollinger FB, Lemon SM, Margolis H, eds. Viral Hepatitis and Liver Disease. Baltimore: Williams & Wilkins, 1990; 76-8.
4. Guidotti LG, Persephone B, Brown A, McClarey H, Koch R, Chisari FV. Noncytopathic clearance of lymphocytic choriomeningitis virus from the hepaptocyte. J. Exp Med. 1999; 189: 1555-64.
5. Boni C, Penna A, Ogg GS et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001; 33: 963-71.
6. Boni C, Bertoletti A, Penna A et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J. Clin. Invest 1998; 102: 968-75.
7. Sing GK, Ladhams A, Arnold S et al. A longitudinal analysis of cytotoxic T lymphocyte precursor frequencies to the hepatitis B virus in chronically infected patients. J. Viral Hepat 2001; 8: 19-29.
8. Vento S, Garofano T, Renzini C et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. New Eng J. Med. 1998; 338: 286-90.
9. Keeffe EB, Iwarson S, McMahon BJ et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998; 27: 881-6.
10. Lee SD. Hepatitis A vaccination in patients with chronic liver disease in Taiwan. J. Viral Hepat 2000; 7: 19-21.
11. Sung JJ. Epidemiology of hepatitis A in Asia and experience with the HAV vaccine in Hong Kong. J. Viral Hepat 2000; 7: 27-8.
12. Cooksley WG. Consensus statement on the role of hepatitis vaccination in patients with chronic liver disease. J. Viral Hepat 2000; 7: 29-30.
13. Advisory Committee on Immunization Practices. Prevention of hepatitis A through active or passive immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR October 01, 1999; 48 (RR12): 1-37.
14. Salleras L. Impact of mass hepatitis A + B vaccination in preadolescents Catalonia (Spain). Vaccinations For All Life Stages, September 8-10, 2002, Barcelona, Spain, 2002.